ReviewTrends in pharmacological sciences2004
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?
Review in Trends in pharmacological sciences, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Pooled it
- The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.Life sciences · 2020Pooled it
- Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.Clinical and experimental immunology · 2024Review
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
- Article
- Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis.Antibodies (Basel, Switzerland) · 2022Review
- Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance.Frontiers in immunology · 2022Review
- A single center experience of intravenous immunoglobulin treatment in Covid-19.International immunopharmacology · 2021Observational
- Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia.Bulletin of the National Research Centre · 2021Review
- Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2021Review
- Immune-Based Therapy for COVID-19.Advances in experimental medicine and biology · 2021Article
- COVID-19: benefits and risks of passive immunotherapeutics.Human vaccines & immunotherapeutics · 2020Review
- Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.Cell reports. Medicine · 2020Review
- Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.Clinical reviews in allergy & immunology · 2020Review
- Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?International journal of molecular sciences · 2020Article
- Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity.Frontiers in microbiology · 2020Article
- Treatment Options for COVID-19: A Review.Frontiers in medicine · 2020Review
- Intravenous Immunoglobulin Therapy EliminatesInternational journal of molecular sciences · 2019Article
- Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1.Frontiers in immunology · 2018Review
- Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.Cellular immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, IVIg provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.